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function.[2] As of 2009, metformin is one of the only two 
oral antidiabetics in the World Health Organization Model 
List of Essential Medicines.[3] Due to this, metformin, 
either used as monotherapy or as combination therapy 
with other oral antidiabetic agents or insulin, has become 
the most widely used antidiabetic drug. Due to widespread 
use, much is known about its side effects (SEs). The most 
dreaded SE of biguanides, lactic acidosis, is never a problem 
with judicious use of metformin.[4] Gastrointestinal SEs 
of metformin can be overcome by initiating metformin 
therapy at a low dose and slowly increasing the dose, by 
giving metformin after meals, or by utilizing a slow-release 
metformin preparation.[5]
ADVERSE EFFECTS OF METFORMIN
One well-documented SE of metformin is malabsorption 
of vitamin B12 (vit B12) and consequently low serum levels 
INTRODUCTION
Not all hazards of a drug are known before marketing. 
Some adverse effects of drugs come to fore only after years 
of use. That is why constant post-marketing monitoring 
is necessary and why clinicians are expected to report all 
adverse effects to the regulatory/monitoring agencies. A 
single case reported in the medical literature can also lead 
to the generation of a signal, and subsequently more cases 
are reported. This forms the core of pharmacovigilance.[1]
In recent times, rare adverse effects due to long-term 
metformin therapy have been reported, thus necessitating 
revision of recommendations. 
Metformin, a biguanide, was introduced in the United 
Kingdom in 1958, in Canada in 1972, and in the United 
States in 1995. It is the drug of first choice for the 
treatment of type 2 diabetes, particularly in overweight 
and obese people and those with normal kidney   
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Monitoring of adverse drug reactions of a drug is a continuous process and runs through-out the life of a drug. 
Many rare adverse effects of a drug are documented after years of use; when a single case (signal generation) 
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of the vitamin. Within the first 10–12 years after it came 
into use, it became evident that long-term metformin 
therapy causes vit B12 malabsorption. Prevalence of vit 
B12 malabsorption was found to be 30% in patients taking 
long-term metformin therapy, and low serum levels of vit 
B12 were found in approximately 20% of patients having 
vit B12 malabsorption.[6] In another study, low serum levels 
of vit B12 were reported in 17.5% of patients using 2 g of 
metformin daily for at least 2 years.[7] 
The first case of vit B12 deficiency–induced megaloblastic 
anemia due to long-term metformin was reported in 
1980. The patient developed megaloblastic anemia after 
8 years of metformin use.[8] Subsequently, more cases 
were reported. In 2007, case of hyperhomocysteinemia-
induced deep vein thrombosis was reported, where the 
hyperhomocysteinemia was apparently caused by long-
term metformin therapy–induced vit B12 deficiency.[9] 
Recently, the first case of peripheral neuropathy due to 
metformin-induced vit B12 deficiency was reported.[10] So, 
what had been feared by early researchers in the field of 
metformin-induced malabsorption – that metformin can 
cause subacute combined degeneration of the cord, which 
can be easily mistaken as diabetic neuropathy – has proved 
true.[6,7] 
REVISTING METFORMIN
Annual measurement of serum vit B12 levels in patients 
on long-term metformin therapy was recommended way 
back in 1970s.[6-8] However, given the present setup of 
primary care centers in developing countries, with the lack 
of adequate laboratory facilities, it is doubtful that such 
monitoring will be possible in all diabetic patients.[11,12]
In any case, this is hardly the routinely-followed method 
in patients on metformin therapy. Moreover, cost-
effectiveness of annual measurement of vit B12 levels will 
also need to be considered, given that the incidence of 
type 2 diabetes is on the rise. Also, it must be remembered 
that vit B12 deficiency–induced neuropathy precedes the 
appearance of megaloblastic anemia. While the anemia 
of vitamin B12 deficiency is reversible, the progress of the 
neuropathy is only arrested and not reversed with initiation 
of vit B12 therapy. Even after measurement of low vit B12 
levels, the differential diagnosis from other causes of vit 
B12 deficiency will be difficult to make. The fact that the 
symptoms of diabetic neuropathy resemble metformin-
induced neuropathy will add to the confusion. 
Thus, annual injections of vit B12 (in a dose of 1 mg) given 
to every patient on long-term metformin therapy will be 
a more practical and cost-effective method. This method 
will ensure replenishment of vit B12 stores for at least 1 
year. It will also obviate the need for annual screening of 
vit B12 levels. 
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